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Selective depletion of fibroblasts preserves morphology and
the functional integrity of peritoneum in transgenic mice with
peritoneal fibrosing syndrome.
Background. A peritoneal fibrosing syndrome (PFS) can
progressively reduce peritoneal ultrafiltration during chronic
peritoneal dialysis in patients with renal failure. The pathogen-
esis of PFS is unclear and the role of peritoneal fibroblasts has
not been evaluated experimentally.
Methods. We followed the fate of fibroblasts producing PFS
in a mouse model using fibroblast-specific protein 1 (FSP1) as
a marker. PFS was induced by daily peritoneal infusions of
chlorhexidine gluconate (CHG) saline into transgenic mice
expressing the thymidine kinase (tk) gene under the control
of the FSP1 promoter (FSP1.tk mice). To demonstrate the
role of fibroblasts in PFS, we treated these FSP1.tk mice with
a nucleoside analogue to induce DNA chain termination and
fibroblast death.
Results. Mice receiving peritoneal infusions of CHG saline
every other day for 2 weeks developed increasing numbers
of FSP1 fibroblasts in the subserosal layers of the visceral
peritoneum. Mac-3 monocytes (macrophages) subsequently
accumulated over the next 2 weeks in association with in-
creased deposition of type I collagen and increased endothelial
vascularity (CD31) in these subserosal tissues. Since these
peritoneal fibroblasts expressed monocyte chemoattractant
protein-1 (MCP-1), heat shock protein 47 (HSP47), and vascu-
lar endothelial growth factor (VEGF), we suspect they were
partially responsible for macrophage recruitment, matrix pro-
duction, and the neoangiogenesis in the subserosal tissue.
Treatment of PFS in FSP1.tk transgenic mice with a nucleo-
side analogue selectively reduced the numbers of peritoneal
fibroblasts and attenuated the attendant changes in peritoneal
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histology. Rescuing the peritoneal membrane from chronic
thickening and neoangiogenesis by reducing the number of
fibroblasts also preserved ultrafiltration.
Conclusion. Peritoneal fibroblasts play a pivotal role in PFS,
and their deletion using a fibroblasts-specific transgene was
effective in preventing peritoneal fibrogenesis.
There is a tendency to lose peritoneal ultrafiltration
and small molecule clearance [1–5] in patients receiving
continuous ambulatory peritoneal dialysis (CAPD).
Within a few months to a year after the initiation of
CAPD, peritoneal membranes undergo a structural dete-
rioration [2, 5–12] associated with membrane thickening
and fibrosis [13]. This disorder is called the peritoneal
fibrosing syndrome (PFS) [14]. Preserving the longevity
of the peritoneal membrane and its relationship to nor-
mal peritoneal physiology is important to the long-term
success of this therapy [1, 2, 5].
The expression of PFS is variable in humans, de-
pending on individual susceptibility to membrane dam-
age or the type of dialysate used for therapy. Long-term
use of nonphysiologic dialysis fluids (low pH, hyperos-
molarity, high glucose concentration, or high lactate), or
contaminants derived from the nonenzymatic degrada-
tion of glucose, repeated bacterial peritonitis, or expo-
sure to some drugs and antiseptics all contribute to PFS
[2, 5, 14, 15]. The expected pathology in PFS seems
independent of its cause [10, 12, 14, 16]. There have
been several animal models of PFS, some of which are
generated by substances currently unused for CAPD
patients such as chlorhexidine [17–25]. However, these
models share a number of similarities to human PFS [13]
and have contributed to its understanding. The role of
fibroblasts in the alteration of the peritoneum has never
been studied in detail because of a dearth of fibroblast-
specific markers.
Several years ago, we cloned fibroblast-specific protein 1
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(FSP1) [26, 27] and demonstrated the presence of fi-
broblasts in fibrosing tissues using anti-FSP1 antibodies
[27–29]. FSP1 fibroblasts remodel tissue architecture in
organ fibrosis [27, 29]. When inflammation initiates tissue
fibrogenesis, FSP1 fibroblasts activate, proliferate, and
produce fibrogenic molecules such as type I and III col-
lagens, fibronectin, and proteoglycans [27, 29]. When tis-
sue inflammation resolves, FSP1 fibroblasts attenuate
through apoptosis, leaving an acellular fibrous scar. With
FSP1 as a marker, we studied a murine model of PFS
to monitor the cell fate and pathophysiologic role of
fibroblasts in the peritoneum challenged by chlorhexi-
dine [30]. Transgenic mice (FSP1.tk) whose fibroblasts
selectively express high levels of herpes simplex virus
thymidine kinase (tk) under the control of the FSP1
promoter [26, 31] were treated with gancyclovir (GCV),
a nucleoside analogue, which corrupts DNA synthesis
by chain termination in dividing cells [31]. By generating
PFS in FSP1.tk mice we asked if fibroblasts depletion
would attenuate peritoneal histopathology or its func-
tional deterioration.
We also focused on the role of macrophages in this study
as they are a source of profibrotic molecules, including
transforming growth factor-1 (TGF-1), platelet-derived
growth factor (PDGF), tumor necrosis factor- (TNF-),
interleukin-1 (IL-1), and fibronectin [29, 32]. These macro-
phages migrate to the peritoneal interstitium and perito-
neal fluid from the circulation through small blood ves-
sels [33]. The stimulus for this efflux is thought to be
chemoattractant molecules, like monocyte chemoattrac-
tant protein-1 (MCP-1), regulated upon activation, nor-
mal T cell expressed and secreted (RANTES), macro-
phage inflammatory protein-1 (MIP-1), which are secreted
by a variety of resident cells such as mesothelial cells,
fibroblasts, or previously recruited macrophages [32, 34].
METHODS
Transgenic mice
FSP1.tk mice were housed individually with free ac-
cess to chow and water and with humidity and tempera-
ture controlled under pathogen-free conditions. Animal
care and treatment conformed to institutional guidelines.
The creation of FSP1.tk mice and their breeding onto
a Balb/c background has been previously described [31].
The FSP1 promoter directs the expression of tk exclu-
sively in FSP1 fibroblasts making these fibroblasts selec-
tively susceptible to the lethal effects of nucleoside ana-
logues either in culture or during experimental fibrosis
[26, 31].
Generation of PFS in FSP1.tk or wild-type mice
Six 8-week-old male mice were maintained chronically
with 21 gauge plastic catheters (Terumo, Tokyo, Japan)
inserted from a position along the high back, through the
retroperitoneum, into the peritoneal cavity. Peritoneal
fibrosis developed in peritoneal fibrosis mice following
intraperitoneal injections of 0.03% chlorhexidine gluco-
nate and 5% ethanol dissolved in 1.0 mL of saline (CHG
saline) through a catheter every other day for 4 weeks.
Control mice were treated with normal saline. Optimal
conditions for producing chronic peritonitis with fibro-
genesis were first determined in pilot studies (data not
shown). In these early pilot studies, there were no sub-
stantial differences in pathology between the visceral
and parietal peritoneum in peritoneal fibrosis mice with
PFS at week 4. Since the surface area of visceral perito-
neum is significantly larger and potentially more impor-
tant as dialysis membrane, and since solid samples of
bowel are easier to process, we used visceral peritoneum
for our pathologic analyses. To minimize loss of mesothe-
lium during tissue harvest, the rest of the intestines were
immediately fixed in 4% paraformaldehyde [phosphate-
buffered saline (PBS)] overnight, and then at least 10
small cylindric samples of bowel wall were randomly cut
from fixed intestine and mounted in paraffin with the
axis being kept vertical to the horizontal surface of the
paraffin block. These tissue samples were used for histo-
pathology and immunohistochemical analyses. The rest
of the fixed bowel samples were rinsed in serial concen-
trations of sucrose solution and then snap-frozen for
immunofluorescence.
Deletion of peritoneal fibroblasts in FSP1.tk
or wild-type mice
To evaluate the effects of GCV on the deletion of
fibroblasts in PFS, FSP1.tk (transgenic) or wild-type
mice were divided into four comparative groups: perito-
neal fibrosis-transgenic, control-transgenic, peritoneal
fibrosis–wild-type, and control-wild-type mice. Perito-
neal fibrosis-transgenic mice (N  10) and peritoneal
fibrosis-wild-type mice (N  10) were treated with a
catheter injection of 1.0 mL of CHG saline at 9:00 a.m.
every other day for 4 weeks. Two weeks after initiation
of CHG saline injections, GCV (kindly provided by F.
Hoffmann, La Roche, Ltd., Basel, Switzerland) in PBS
was also injected through the catheter (50mg/kg weight)
at 9:00 p.m. every day for 2 weeks. Control-transgenic
mice (N  8) and control-wild-type mice (N  9) re-
ceived normal saline instead of CHG saline as above,
and were likewise treated with GCV over the last 2
weeks of the experiment. During the study, mice losing
a catheter were excluded from the data analysis (three
mice from the control groups). Preliminary studies re-
vealed that 2 weeks of GCV treatment did not yield any
pathology in the peritoneal tissue of transgenic or wild-
type mice (data not shown). All groups therefore re-
ceived GCV in these experiments. At the end of the
study, a modified peritoneal equilibrium test (PET) was
carried out on each test subject and then tissue samples
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were harvested for histopathologic evaluation and direct
enzyme-linked immunosorbent assay (ELISA).
Flow cytometric analyses
Splenocytes were liberated from the spleens of peri-
toneal fibrosis-transgenic, peritoneal fibrosis-wild-type,
control-transgenic, and control-wild-type mice by sieving
through a nylon mesh. The cells were washed in PBS
four times, and then incubated in hemolysis buffer (0.15
mol/L NH4Cl, 1 mmol/L KHCO3, 0.1 mmol/L Na2 ethyl-
enediaminetetraacetic acid (EDTA) at pH 7.4) at room
temperature for 5 minutes with occasional shaking [35].
The splenocytes were next washed in staining buffer
[PBS with 1% bovine serum albumin (BSA)] four times
and 50 L aliquots of 106 cells were then incubated with
various antibodies: monoclonal rat antimouse macro-
phages (Mac-3) (1:50) (PharMingen, San Diego, CA,
USA), or fluorescein isothiocyanate (FITC)-conjugated
rat antimouse CD4 or antimouse CD8 (PharMingen) for
20 minutes on ice; FITC-conjugated goat antirat immu-
noglobulin G (IgG) (1:100) was used for secondary stain-
ing of macrophage-labeled cells. All samples were then
washed twice with staining buffer and fixed with 1%
paraformaldehyde in PBS. The fixed cell samples were
stored at 4C under shade until scanned. FCASscan anal-
ysis (Becton-Dickinson, Franklin Lakes, NJ, USA) was
performed on 104 cells using CellQuest software. Control
cells were scanned with isotope-matched rat IgG and
FITC-conjugated antibodies.
Histopathology, immunohistochemistry,
and immunofluorescence
Four micron sections were cut from paraffin blocks
and processed for hematoxylin-eosin staining or indirect
immunoperoxidase staining. For the latter, after deparaf-
finization and rehydration, the sections were treated with
proteinase K and boiled by microwave in citrate buffer
for unmasking. Next, the sections were immersed in 3%
H2O2 in methanol in order to inhibit endogenous peroxi-
dase and nonspecific reaction products before flooding
with 5% BSA in PBS. Rabbit anti-FSP1 (1:500) [27, 28],
rabbit anti-type I collagen (1:400) [36], rat anti-Mac-3
(1:50), and rat anti-platelet-endothelial cell adhesion
molecule-1 (PECAM-1) (CD31) (1:50) (PharMingen)
were applied as primary antibodies followed by immu-
noenzyme reaction using biotin-conjugated antirabbit
IgG or antrat IgG (1:500) (American Qualex, San Cle-
mente, CA, USA), and a Vectastain ABC Standard Kit
(Vector Laboratories, Burlingame, CA, USA). Reaction
development was accomplished using diaminobenzidine
(DAB) as substrate (for detection of CD31, more inten-
sive digestion and longer microwave exposure were
needed). Ten visceral peritoneal fields at 150 magnifi-
cation were assessed quantitatively in each immuno-
stained section using a color image computer analyzer
(Mac SCOPE, version 2.5, Mitani Corp., Hukui, Japan).
Immunohistochemical stainings were expressed as %
area of reaction product within the subserosal stroma
between the mesothelium and intestinal smooth muscle
layer, including the mesothelium. Single or dual immu-
nofluorescence was performed on 4m cryostat sections.
The primary antibodies were employed as follows: goat
anti-heat shock protein 47 (HSP47) (1:100) (Santa Cruz
Biotechnology, Santa Cruz, CA, USA), anti-MCP-1
(1:100) (Santa Cruz Biotechnology), anti-vascular endo-
thelial growth factor (VEGF) (1:100) (Santa Cruz Bio-
technology), rabbit anti-FSP-1 (1:500), anti-tk protein
(1:500) (generous gift from W.C. Summers, Yale Univer-
sity) conjugated with FITC using a FITC Protein Label-
ing Kit (Boehringer Mannheim GmbH, Mannheim, Ger-
many), rat anti-Mac-3 (1:50), or FITC-conjugated rat
antimouse CD4 and antimouse CD8 were used; a second-
ary antibody (Rhodamine-conjugated antigoat IgG and
antirabbit IgG (1:500) (Chemicon International, Teme-
cula, CA, USA) or FITC-conjugated anti-rabbit IgG and
anti-rat IgG (1:500; American Qualex)) followed where
necessary. These sections were analyzed under confocal
microscope (MRC600) (Bio-Rad Laboratories, Hercules,
CA). All of the secondary antibodies were isolated by
immunoaffinity chromatography and absorbed for dual
labeling. Control measures included omitting the pri-
mary antibody or substituting the primary antibody with
species-specific normal IgG.
Detection of apoptotic cells
DNA fragmentation within apoptotic cell nuclei was
detected using the MEBSTAIN Apoptosis Kit Direct
(Medical and Biological Laboratories, Nagoya, Japan).
After deparaffinization and treatment with proteinase K,
histologic sections were incubated for 1 hour at 37C with
FITC-deoxyuridine triphosphate (dUTP) and terminal
deoxynucleotidyl transferase, the latter linking FITC-
dUTP to the 3	-OH fragmented ends of DNA. Immuno-
cytochemistry with anti-FSP1 antibody and Rhodamine-
conjugated antirabbit IgG was performed to colocalize
apoptosis with FSP1 expression.
Indirect ELISA
Some of the small bowel tissues were sonicated in a
cold radioimmunoprecipitation assay (RIPA) lysis buffer
[1% nitroprusside-40, 0.1% sodium dodecyl sulfate
(SDS), 100 g/mL phenylmethylsulfonylfluoride, 0.5%
sodium deoxycholate, 1 mmol/L sodium orthovanadate,
2 g/mL aprotinin, 2 g/mL antipain, and 2 g/mL leu-
peptin in PBS), and the homogenates were centrifuged
for 5 minutes at 4C. The protein concentration in the
supernatant was determined using a BCA Protein Assay
Kit (Pierce, Rockford, IL, USA). Ninty-six-well multiti-
ter ELISA plates were coated in triplicate with 5 g
of protein sample/well [36]. The plates were incubated
overnight at room temperature. After coating, the plates
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were washed three times with 0.15 mol/L NaCl and
0.05% Tween 20 washing solution. After washing, the
plates were blocked with 2% BSA and 0.1% Tween 20
in PBS buffer for 30 minutes at 37C. After blocking,
the plates were rewashed with washing solution and then
incubated with rabbit anti-type I collagen (1:1000) in
incubation buffer for 1 hour at room temperature. Preim-
mune serum was used as control. The plates were re-
washed and incubated with alkali phosphatase-conju-
gated antirabbit IgG (1:1000) (Sigma Chemical Co., St.
Louis, MO, USA) in incubation buffer for 1 hour at
room temperature. After washing thoroughly, substrate,
disodium p-nitrophenyl phosphate (5 g/mL) (Sigma
Chemical Co.) was added, and the absorbance was mea-
sured with an ELISA autoreader (Microplate Reader
Model 3550) (Bio-Rad) at 450 nm.
Plasma biochemistry
At the end of the study, plasma samples collected from
3 mice in each group that did not receive PET were
analyzed biochemically. The serum albumin levels were
determined with the bromcresol green method (A/G B
test, Wako, Osaka, Japan). Blood urea nitrogen, creati-
nine, total cholesterol, alanine aminotransferase, and al-
kaline phosphatase levels were measured with an auto-
analyzer (Dry-Chem 3000, Fuji, Tokyo, Japan).
Modified PET
Modified PET was carried out to determine the ultra-
filtration capacity of peritoneum following PFS. Five mil-
liliters of 7% glucose dialysis fluid was instilled into the
peritoneal cavity and maintained there for 2 hours. At
the end of the PET, each mouse was sacrificed by cervical
dislocation under ether anesthetic. Remaining CAPD
fluid was drained through the catheter, and then laparot-
omy was performed to collect residual intraperitoneal
fluid and tissue samples. The drainage volume was
weighed, and the glucose concentration was determined
with Dry-Chem 3000.
Statistical analysis
Values were presented as means 
 SE. Statistical dif-
ferences between groups were evaluated by analysis of
variance, followed by Duncan’s multiple range test, with
P  0.05 used to detect significance.
RESULTS
General observations in mice with PFS
Chronic administration of saline for 4 weeks in control
mice (Fig. 1) did not significantly alter the visceral perito-
neum (representative section; Fig. 2A). Although chronic
administration of CHG saline into the peritoneal cavity
was not lethal, most PFS mice did not gain weight during
the 4 weeks study period. After 2 weeks of every other
day administration of CHG, the visceral peritoneal his-
tology from PFS mice demonstrated a mesothelium
largely intact with a thickened subserosa. By week 4, the
subserosal peritoneal tissue of PFS mice was significantly
thickened with fibrocellular components (representative
sections; Fig. 2 B and C); FSP1 fibroblasts were beginning
to accumulate at week 2 (Fig. 2E) and in greater numbers
by week 4 (Fig. 2F) compared to the subserosa of control
mice (Fig. 2D). Most of the other cells in the subserosa of
PFS mice were Mac-3 macrophages (Fig. 2G); Mac-3
cells were FSP1 by FACSscan (data not shown). CD4
and CD8 T lymphocytes were only identified occasion-
ally in the subserosal peritoneum of PFS mice (data
not shown). Furthermore, increased deposition of type I
collagen and an increased number of CD31 vascular
endothelial cells in the subserosal peritoneum of PFS
mice were found in fibrotic areas (Fig. 2 H and I). The
numbers of FSP1 fibroblasts and Mac-3 macrophages,
the amount of type I collagen and the extent of vascu-
larity in the subserosal tissue each increased over time
(P  0.05) (Fig. 3). Although the number of Mac-3
macrophages were fewer than the number of FSP1 fi-
broblasts throughout the study, the macrophages in-
vaded the subserosal tissue at weeks 1 to 2 before the
fibroblasts increased in the number (Fig. 3 A and B). The
presence of proliferating fibroblasts and infiltrating mac-
rophages was followed by increasing deposits of type I
collagen and neoangiogenesis (Fig. 3 C and D). Dual
immunocytochemistry of the subserosal peritoneum of
PFS mice revealed that most of the MCP-1, HSP47, or
VEGF stromal cells were simultaneously positive for
FSP1 (Fig. 4 A to C), suggesting that peritoneal fibroblasts
play a role in the enrollment of macrophages, collagen
production, and neoangiogenesis in PFS. Overall, the
peritoneal histology in control mice was nearly normal,
and chronic insertion of the catheter itself, at least for
4 weeks, did not cause any substantial changes to the
visceral peritoneum. All the controls for immunohisto-
chemistry were without significant background signals.
Deletion of fibroblasts in mice with PFS
In preliminary studies, we evaluated several general
parameters prior to undertaking the deletion experi-
ments. First, flow cytometric analysis of splenocytes de-
rived from FSP1.tk mice, with or without GCV treat-
ment, revealed no remarkable alterations in the cellular
composition of the spleen. For example, the percentage
of CD4 and CD8 T lymphocytes, and Mac-3 macro-
phages from FSP1.tk mice receiving GCV were 27%

2%, 14%
 2%, and 27%
 3%, respectively, and 23%

2%, 11% 
 2%, 24% 
 2%, respectively, in FSP1.tk
mice not receiving GCV. Second, we observed in perito-
neal fibrosis-transgenic mice that fibroblasts in the peri-
toneum at week 2 were simultaneously positive for tk
protein and FSP1 (Fig. 4d). Third, a nonlethal dose of
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Fig. 1. Murine model of peritoneal fibrosing syndrome (PFS). (A ) A 21 gauge plastic catheter was inserted from the back into the peritoneal
cavity, fixed to the back skin, and maintained for 4 weeks. Each mouse was kept individually in one cage. (B ) The catheter tip was located
intraperitoneally (arrow). After each insertion procedure, normal saline was infused and drained through the catheter to confirm the location of
the catheter tip.
Fig. 2. Typical histopathology of murine peritoneal fibrosing syndrome (PFS). (A ) Visceral peritoneum of control-wild-type mice at week 4.
Subserosal stroma was thin and few cellular components were observed (hematoxylin-easin stain, 150). (B ) Visceral peritoneum of peritoneal
fibrosis-wild-type mice at week 2. Subserosal stroma was thickened (arrows) and contained cellular components (hematoxylin-eosin stain, 150).
(C) Visceral peritoneum of peritoneal fibrosis-wild-type mice at week 4. Subserosal stroma was significantly thickened (arrows) and both cellular and
acellular areas were observed. Much of mesothelium remained intact (arrowheads) (hematoxylin-eosin stain, 150). (D) There were few fibroblast-
specific protein-1 (FSP1) fibroblasts in the subserosal stroma of control-wild-type mice at week 4 diaminobenzidine (DAB) (150). (E) There were
numerous FSP1 fibroblasts in the subserosal stroma (arrows) of peritoneal fibrosis-wild-type mice at week 2 (DAB, 150). (F) These FSP1
fibroblasts in the cellular area of the subserosal stroma (arrows) remained in peritoneal fibrosis-wild-type mice at week 4 (DAB, 150). (G) There
were a number of Mac-3 macrophages in the subserosal stroma (arrows) of peritoneal fibrosis-wild-type mice at week 2 (DAB, 150). (H) There
was significant deposition of type I collagen in the subserosal stroma (arrows) in peritoneal fibrosis-wild-type mice at week 4 (DAB, 150). (I) The
thickened subserosal tissue in peritoneal fibrosis-wild-type mice at week 4 was rich in CD31 small vessels (arrows) (DAB, 200).
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Fig. 3. Quantitative assessment of fibroblast-
specific protein-1 (FSP1) fibroblasts, Mac-3
macrophages, and extent of type I collagen
deposition in peritoneal fibrosis-wild-type
mice. (A ) The number of FSP1 fibroblasts in
the subserosal stroma significantly increased
over time. (B ) The number of Mac-3 macro-
phages in the subserosal stroma significantly
increased by week 2 and remained until week
4. (C ) The amount of type I collagen deposi-
tion in the subserosal stroma of the perito-
neum increased significantly by week 4. (D )
The hypervascularity in the subserosal stroma
was significant at week 4.
GCV (50 mg/kg) once a day by catheter infusion was
well tolerated for a treatment protocol of 2 weeks (data
not shown). Finally, the metabolic profile of mice from
all groups was not significantly different from each other
(data not shown).
In experiments to formally test the role of peritoneal
fibroblasts in mice with PFS, the visceral peritoneum of
peritoneal fibrosis-wild-type  GCV mice after 4 weeks
of CHG saline were fibrotic and significantly thickened
compared to peritoneal fibrosis-transgenic  GCV mice
(Fig. 5 A and B), and seemed substantially similar to
peritoneal fibrosis mice in the pilot study. Apoptosis was
induced exclusively in FSP1 fibroblasts (Fig. 4E) in
peritoneal fibrosis-transgenic mice with exposure to GCV
such that the number of FSP1 fibroblasts in the perito-
neum was significantly reduced below those in peritoneal
fibrosis–wild-type mice. The percentage of the apoptotic
nuclei was 45.5% 
 5.5% among 40 
 4 FSP1 fibro-
blasts observed in a 300 field of subserosal stroma from
peritoneal fibrosis-transgenic mice at week 4, but only
2.0% 
 0.4% among 49 
 5 FSP1 fibroblasts in perito-
neal fibrosis-wild-type mice (P  0.05) (Figs. 5 C and D
and 6 A).
When the proliferation of FSP1 fibroblasts was atten-
uated in peritoneal fibrosis-transgenic mice receiving
GCV, the number of Mac-3 macrophages and CD31
endothelial cells, and the accumulation of type I collagen
were also reduced in the peritoneum of peritoneal fibro-
sis-transgenic mice (P 0.05) (Figs. 5 E to I and 6 B to D),
leaving the subserosal tissues of the visceral peritoneum
in peritoneal fibrosis-transgenic mice considerably intact.
The peritoneum of control-transgenic mice and control-
wild-type mice had no significant abnormalities (data not
shown). Quantification analyses by indirect ELISA also
demonstrated that deletion of fibroblasts in peritoneal
fibrosis-transgenic mice treated with GCV reduced type
I collagen deposition to control levels (P  0.05) (Fig. 7).
Modified PET
At the conclusion of the 4 week study, each group of
mice (peritoneal fibrosis-transgenic, peritoneal fibrosis-
wild-type, control-transgenic, and control-wild-type) un-
derwent a modified PET. The drainage volume and glu-
cose concentration of each group were measured (Fig.
8). These indices were significantly lower in peritoneal
fibrosis-wild-type  GCV mice compared to those mea-
sured in peritoneal fibrosis-transgenicGCV mice (P
0.05), suggesting that selective deletion of fibroblasts in
peritoneal fibrosis-transgenic mice reduced glucose ab-
sorption and preserved ultrafiltration.
DISCUSSION
We observed that the number of FSP1 fibroblasts
in the subserosal stroma of mice with PFS increased
significantly over a 4-week interval following chronic
exposure to CHG saline. At week 2, the PFS lesions
generated in peritoneal fibrosis-transgenic mice showed
increasing numbers of FSP1 fibroblasts. GCV treatment
started at that time for an additional 2 weeks rescued
the peritoneum from PFS by decreasing the number of
fibroblasts to the control levels via apoptosis. Our ap-
proach to peritoneal rescue was associated with a de-
crease in monocyte infiltration, collagen deposition, and
neoangiogenesis.
Since studies of fibroblasts in vivo have been limited
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Fig. 4. Characterization of peritoneal fibroblast-specific protein-1
(FSP1) fibroblasts in the subserosal stroma. (A ) Immunofluorescence
of FSP1 (in red) and monocyte chemoattractant protein-1 (MCP-1) (in
green) in peritoneal fibrosis-wild-type mice at week 4. There were some
stromal cells in yellow in the subserosal stroma, indicating that some
fibroblasts produced MCP-1 (merged image, 150). (B ) Using two
labels, FSP1 (in red) and heat shock protein 47 (HSP47) (in green),
there were some stromal cells in yellow in the subserosal stroma of
peritoneal fibrosis-wild-type mice at week 4, indicating that FSP1
fibroblasts contributed to collagen production (merged image, 150).
(C ) Immunofluorescence of FSP1 (in red) and vascular endothelial
growth factor (VEGF) (in green) in peritoneal fibrosis-transgenic mice
at week 2. Some of FSP1fibroblasts in the subserosal stroma (in yellow)
were simultaneously positive for VEGF, suggesting their contribution to
neoangiogenesis (merged image, 150). (D ) Immunofluorescence of
FSP1 (in red) and thymidine kinase (tk) protein (in green) in peritoneal
fibrosis-transgenic mice at week 2. FSP1 fibroblasts in the subserosal
stroma were simultaneously positive for tk protein, yielding yellow
color (merged image, 150). (E ) Many of the FSP1 fibroblasts were
selectively killed by gancyclovir (GCV) treatment via apoptosis
(arrows) on colocalization of FSP1 expression (in red) and apoptotic
nuclei (in green) in peritoneal fibrosis-transgenic mice at week 4 follow-
ing GCV treatment (merged image, 300). Abbreviations are: SL,
serosal layer; SSS, subserosal stroma; ML, muscular layer.
by a lack of fibroblasts-specific markers, we took advan-
tage of the marker, FSP1 [27, 29]. FSP1 belongs to the
S-100 superfamily and is associated with the regulation
of cell shape and motility [27, 36]. Using anti-FSP1 anti-
body, we have previously demonstrated that the number
of FSP1 fibroblasts increase in parallel with the progres-
sion of renal fibrosis [27, 28, 31]. The same was true in
the present study. Our FSP1.tk transgenic mouse on
exposure to GCV had some additional advantages, one
of which is that GCV administration induces apoptosis
Fig. 5. Typical histopathology of peritoneal fibroblast-specific protein
(PFS) in peritoneal fibrosis-transgenic and peritoneal fibrosis-wild-type
mice treated with gancyclovir (GCV). (A ) The subserosal stroma of
the visceral peritoneum (arrows) in peritoneal fibrosis-wild-type mice
was thickened and fibrous (hematoxylin-eosin stain, 150). (B ) With
GCV treatment, the subserosal stroma of the visceral peritoneum
(arrows) in peritoneal fibrosis-transgenic mice remained thin and con-
tained few cellular components (hematoxylin-eosin stain, 150). (C )
There were a number of fibroblast-specific protein-1 (FSP1) fibroblasts
in the subserosal stroma (arrows) from peritoneal fibrosis-wild-type
mice diaminobenzidine (DAB) (150). (D ) GCV treatment reduced
the number of FSP1 fibroblasts in the subserosal stroma (arrows) of
peritoneal fibrosis-transgenic mice (DAB, 150). (E ) There were a
number of Mac-3 macrophages in the subserosal stroma (arrows) of
peritoneal fibrosis-wild-type mice (DAB, 150). (F ) GCV treatment
reduced the number of Mac-3 macrophages in the subserosal stroma
of peritoneal fibrosis-transgenic mice (DAB, 150). (G ) There was a
significant deposition of type I collagen in the subserosal stroma
(arrows) of peritoneal fibrosis-wild-type mice (DAB, 150). (H ) There
was no significant deposition of type I collagen in the subserosal stroma
of peritoneal fibrosis-transgenic mice (DAB, 150). (I ) Increased vas-
cularity by CD31 staining was evident in the subserosal tissue of perito-
neal fibrosis-wild-type mice (arrows) (DAB, 200). (J ) There was no
significant vascularity in the subserosal tissue of peritoneal fibrosis-
transgenic mice (DAB, 200).
only in proliferating fibroblasts [31]. This approach works
in connective tissues (peritoneum) as well as in complex
organs [26, 31].
In the early days of CAPD in humans, it was believed
that regular exposure of peritoneal membranes to anti-
septics might reduce the risk of peritonitis [14]. However,
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Fig. 6. Quantitative assessment of peritoneal
fibroblast-specific protein (PFS) histopathol-
ogy in peritoneal fibrosis-transgenic (PF-tg)
and peritoneal fibrosis-wild-type (PF-wt) mice
treated with gancyclovir (GCV). (A) The num-
ber of fibroblast-specific protein-1 (FSP1)
fibroblasts in peritoneal fibrosis-transgenic
mice was significantly reduced to the control
levels (Ct-wt and Ct-tg) by GCV treatment.
(B ) The number of Mac-3 macrophages in
peritoneal fibrosis-transgenic mice was re-
duced to control levels with GCV. (C ) The
amount of type I collagen deposited in the
peritoneum of peritoneal fibrosis-transgenic
mice was also maintained at control levels by
deletion of fibroblasts. (D ) Neoangiogenesis
was also inhibited in the subserosal tissue of
peritoneal fibrosis-transgenic mice.
Fig. 7. Quantitative analysis of type I collagen in the peritoneal subser-
osa by indirect enzyme-linked immunosorbent assay (ELISA). The
amount of type I collagen deposited in small bowel subserosa of perito-
neal fibrosis-wild-type (PF-wt)mice treated with gancyclovir (GCV) was
significantly greater than in peritoneal fibrosis-transgenic mice (PF-tg).
Collagen in these peritoneal fibrosis-transgenic mice was significantly
reduced to control levels (Ct-wt and Ct-tg) by deletion of fibroblasts
following GCV treatment.
exposure to chlorhexidine in alcohol was identified early
as responsible for an outbreak of sclerosing peritonitis
[30]. This observation was confirmed by toxicologic ex-
periments in animals [17, 19, 30, 37]. Accordingly, we
introduced chlorhexidine into the peritoneum of mice
to generate PFS [19, 30, 38]. Constant exposure of the
mesothelium to chlorhexidine is thought to disrupt meso-
thelial tight junctions followed by crystalline damage to
the subserosal stroma [14, 30]. Persistent serositis results
from prolonged exposure to this or other toxic metabo-
lites and creates an inflammatory response that predis-
poses to PFS.
Recent studies in CAPD patients suggest that peri-
toneal fibroblasts may derive from mesothelium by epi-
thelial-mesenchymal transition [13]. Based on in vitro
observations, peritoneal fibroblasts both respond to pro-
inflammatory stimuli with proliferation and increased
synthesis of matrix, and contribute to the cytokine net-
work secreting immunologically active molecules into
the peritoneum [39]. We demonstrated by immunofluo-
rescence that FSP1 fibroblasts in the peritoneum ex-
press MCP-1, a macrophages chemoattractant [40], and
HSP47, a collagen chaperone [41]. The deletion of fi-
broblasts significantly reduced the number of infiltrating
macrophages and the accumulation of type I collagen in
the peritoneum, suggesting that fibroblasts are involved
in the enrollment of circulating macrophages and the
production of type I collagen. At an early phase of PFS,
macrophages are attracted by activated resident cells in
the peritoneum, including mesothelial cells, fibroblasts,
and infiltrated macrophages themselves [42–44]. Fur-
thermore, fibroblasts likely anchor infiltrating macro-
phages, and fibroblast deletion subsequently erased the
macrophages that would have otherwise infiltrated the
subserosal tissue (Figs. 2G and 5F). These infiltrating
macrophages can accelerate fibrogenesis by releasing
profibrogenic cytokines and the fibroblasts growth fac-
tors described above [29, 45]. The reduction in their num-
bers might indirectly attenuate PFS. Our findings suggest
that macrophages and fibroblasts cofacilitate each other,
leading to a vicious cycle perpetuating fibrogenesis, and
that deletion of FSP1 fibroblasts can interrupt this cycle.
The degree of experimental fibrosis may depend on the
strain variability of mice. Compared to other strains,
Balb/c mice (like we used in this study) may not form
extensive fibrotic tissue under some experimental condi-
tions [46–48]. We nevertheless observed significant peri-
toneal fibrosis in Balb/c mice.
We also observed enhanced glucose absorption and
loss of ultrafiltration capacity in peritoneal fibrosis-wild-
type mice treated with GCV. This functional deteriora-
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Fig. 8. Modified peritoneal equilibrium test (PET). (A ) The volume
of fluid drained from peritoneal fibrosing syndrome (PFS) mice. The
volume of fluid drained from peritoneal fibrosis-wild-type (PF-wt) mice
was significantly less than that of peritoneal fibrosis-transgenic mice
(PF-tg) treated with gancyclovir (GCV) (P  0.05), and similar to the
control levels (Ct-wt and Ct-tg) in mice not treated with chlorhexidine
gluconate (CHG) saline. This suggests that ultrafiltration capacity was
preserved in peritoneal fibrosis-transgenic mice by deletion of fibro-
blasts compared to peritoneal fibrosis-wild-type mice. (B ) The glucose
concentration of drained fluid in peritoneal fibrosis-wild-type mice was
significantly lower (P  0.05) than that of peritoneal fibrosis-transgenic
mice treated with GCV, and similar to the control levels in mice not
treated with CHG saline. This suggests that the ultrafiltration failure
observed in peritoneal fibrosis-wild-type mice was due to the increased
diffusion of glucose through the peritoneal membrane.
tion of the peritoneum is similar to the same well-known
complication of long-term CAPD. Several different mecha-
nisms for loss of filtration across the peritoneum have
been described [1, 49–51]. Some authors emphasize the
role of increased solute transport to explain the loss of
ultrafiltration due to peritoneal hypervascularity [52, 53],
whereas others suggest the possible impact of changing
lymphatic or peritoneal fluid absorption into peritoneal
tissue [54, 55]. A third possibility is that the formation
of adhesions and sclerosis results in a hyperpermeable
peritoneum even with loss of surface area [1]. Finally,
impaired efficiency of the osmotic agent in peritoneal
dialysate, without change in solute transport, may con-
tribute to loss of ultrafiltration, perhaps related to alter-
ations in transcellular water channels (aquaporin-1) in
the vascular endothelium [56–58]. Among these mecha-
nisms, enhanced glucose absorption due to hypervascu-
larity in the peritoneal membrane is the most common
explanation for loss of ultrafiltration in CAPD [51–53].
In the present study, we also observed that fibroblasts
express VEGF, an angiogenic growth factor, which might
be involved in neoangiogenesis of subserosal tissue
[53, 59]. Several investigators reported that fibroblasts
producing VEGF provide a basic framework for prolif-
erating endothelial cells that form vascular structures
[60–62]. Therefore, antifibrotic therapy by deleting
FSP1 fibroblasts may be important in the prevention of
CD31 neoangiogenesis in subserosal tissue. We suggest
that controlling the number of FSP1 fibroblasts assists
in maintaining mesothelial architecture, while reducing
the infiltration of macrophages, collagen accumulation,
and neoangiogenesis that preserves peritoneal function.
Although CAPD patients are not given chlorhexidine
any more, there are a growing number of patients on
CAPD suffering from PFS and ultrafiltration failure [1–5,
12, 14]. The histopathologic findings in our model of PFS
are similar to the peritoneal characteristics of CAPD
patients after a couple of episodes of peritonitis [12, 14,
63] and supports the clinical relevance of our experimen-
tal system. A few experimental trials to prevent PFS
using pirfenidone or glycosaminoglycans have been re-
ported [11, 19]. To our knowledge, it is the first study
demonstrating that peritoneal fibroblasts play a pivotal
role in the process of PFS. Their conditional deletion
has therapeutic potential.
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